MAP Kinase Kinase Kinase 1
"MAP Kinase Kinase Kinase 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 195-kDa zinc finger motif-containing MAP kinase kinase kinase with broad specificity for MAP KINASE KINASES. It localizes to the CYTOSKELETON and can activate a variety of MAP kinase-dependent pathways.
| Descriptor ID |
D048728
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.559.100 D12.644.360.400.100 D12.776.476.400.100
|
| Concept/Terms |
MAP Kinase Kinase Kinase 1- MAP Kinase Kinase Kinase 1
- MEKK1 Protein
- Mitogen-Activated Protein Kinase Kinase Kinase 1
- Mitogen Activated Protein Kinase Kinase Kinase 1
- MEKK-1 Protein Kinase
- MEKK 1 Protein Kinase
- Protein Kinase, MEKK-1
- MEK Kinase 1
- MEKK1 Protein Kinase
- MAP3K1 Protein
- MAP ERK Kinase Kinase 1
|
Below are MeSH descriptors whose meaning is more general than "MAP Kinase Kinase Kinase 1".
Below are MeSH descriptors whose meaning is more specific than "MAP Kinase Kinase Kinase 1".
This graph shows the total number of publications written about "MAP Kinase Kinase Kinase 1" by people in this website by year, and whether "MAP Kinase Kinase Kinase 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2000 | 2 | 0 | 2 |
| 2001 | 2 | 0 | 2 |
| 2002 | 3 | 0 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 1 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "MAP Kinase Kinase Kinase 1" by people in Profiles.
-
The prognostic effects of somatic mutations in ER-positive breast cancer. Nat Commun. 2018 09 04; 9(1):3476.
-
The MAPK Kinase Kinase GmMEKK1 Regulates Cell Death and Defense Responses. Plant Physiol. 2018 10; 178(2):907-922.
-
CD271+ Cells Are Diagnostic and Prognostic and Exhibit Elevated MAPK Activity in SHH Medulloblastoma. Cancer Res. 2018 08 15; 78(16):4745-4759.
-
Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. Clin Cancer Res. 2017 08 01; 23(15):4027-4034.
-
Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors. Invest New Drugs. 2017 10; 35(5):616-626.
-
Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. Oncotarget. 2016 Jun 28; 7(26):39595-39608.
-
MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model. Mol Cancer Ther. 2015 Dec; 14(12):2773-81.
-
CSN6 positively regulates c-Jun in a MEKK1-dependent manner. Cell Cycle. 2015; 14(19):3079-87.
-
Differential regulation of c-Jun protein plays an instrumental role in chemoresistance of cancer cells. J Biol Chem. 2013 Jul 05; 288(27):19321-9.
-
Comprehensive molecular portraits of human breast tumours. Nature. 2012 Oct 04; 490(7418):61-70.